Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Two clinical trials using combination therapy in adult patients with multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.18
Views: 439

Dr Irene M. Ghobrial - Dana-Farber Cancer Institute, Boston, USA

Dr Irene Ghobrial speaks to ecancer at ASH 2018 about two clinical trials for multiple myeloma in adults.

The first of these trials was a a Phase Ib/II study of the novel anti-CXCR4 antibody ulocuplumab in combination with lenalidomide plus low-dose dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.

The second was a Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smouldering multiple myeloma.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation